Cancer uses abdominal stem cells to fuel growth and metastasis

December 3, 2014
Rice University researchers (from left) Deepak Nagrath, Xinran Liu, Kevin Chen and Bahar Salimian co-authored a new study that shows how ovarian tumors fuel their growth by co-opting a specific type of adult stem cell from abdominal tissues. Credit: Jeff Fitlow/Rice University

(Medical Xpress)—New research from Rice University and the University of Texas MD Anderson Cancer Center shows how ovarian tumors co-opt a specific type of adult stem cell from abdominal tissues to fuel their growth. The research, published online last week in the journal Cancer Research, suggests a new way to target aggressive ovarian cancers by disrupting the metabolic processes that allow them to thrive.

"The presence of a particular type of stem cell known as 'omental adipose stromal cells,' or O-ASCs, has been associated with ovarian tumor proliferation, migration and drug resistance, but the exact role of the stem cells was unknown," said Rice's Deepak Nagrath, lead researcher on the research paper. "We found that O-ASCs supply with metabolites they need to produce nitric oxide, a key signaling molecule that is known to increase blood flow."

Nagrath is director of Rice's Laboratory for Systems Biology of Human Diseases, which specializes in analyzing the unique metabolic profiles of various types of cancer. Cancer researchers first noticed metabolic differences between cancer cells and 80 years ago, when German chemist Otto Warburg made the Nobel Prize-winning discovery that cancer cells produced far more energy from glycolysis than did normal cells. For decades, scientists believed the "Warburg effect" applied to all cancers, but research in Nagrath's lab and others have found that each type of cancer has its own metabolic signature.

For example, in a study published in May, Nagrath and colleagues found that highly aggressive were glutamine-dependent and that depriving the cells of external sources of glutamine—as some experimental drugs do—was an effective way to kill late-stage ovarian cancer cells in the lab.

New research by Rice University scientists Deepak Nagrath (top), Bahar Salimian and colleagues suggests a new way to target aggressive ovarian cancers by disrupting the metabolic processes that allow them to thrive. Credit: Jeff Fitlow/Rice University

In the new study, lead co-author Bahar Salimian, a graduate student in Nagrath's lab, conducted a series of experiments to study the complex interplay between O-ASCs and ovarian cancer cells.

O-ASCs are a type of adult stem cell found in the omentum, a sheet of tissue in the lower abdomen that is one of the most frequent sites of metastasis for ovarian cancer. Previous research had shown that ovarian cancer cells produce far more nitric oxide than healthy ovarian cells. The ovarian cancer cells both deplete their supplies of arginine, the raw material they convert to produce nitric oxide, and they excrete citrulline, a byproduct of the conversion of arginine-nitric oxide conversion.

"When we co-cultured the two cell types in the lab, we found that cancer cells used arginine that was secreted by the stem cells, and that the cancer cells, in burning through that arginine, released citrulline, which in turn caused the stem cells to produce more arginine," Salimian said.

Nagrath said the mutually dependent relationship between the stem cells and cancer cells frees ovarian tumor cells from some of the normal metabolic stresses they would otherwise face in their race to grow and also allows them to resist attacks from some chemotherapeutic drugs.

"Our findings suggest that O-ASCs upregulate glycolysis and reduce oxidative stress in cancer cells by increasing nitric oxide levels," Nagrath said. "Significantly, we also found that O-ASC-mediated chemoresistance in cancer cells can be deregulated by altering the balance of nitric oxide that the cancer relies upon."

Nagrath said a multidrug cocktail that disrupts the signals between the and the cancer cells could upset the metabolic balance that relies upon to fuel its metastatic growth.

"A combined approach of targeting secreted arginine with the enzyme L-arginase, along with targeting microenvironment-secreted factors with the synthesis inhibitor L-NAME may be a viable therapeutic approach for targeting ovarian and endometrial cancers," Nagrath said.

Explore further: Mesothelial cells promote ovarian cancer metastasis

More information: A copy of the Cancer Research paper is available at:
cancerres.aacrjournals.org/con … CAN-14-1337.abstract

Related Stories

Mesothelial cells promote ovarian cancer metastasis

September 9, 2014
Less than half of the women diagnosed with ovarian cancer will survive beyond 5 years. Ovarian cancer readily spreads to abdominal organs, which are covered by a layer of cells called the mesothelium. Ovarian cancer cells ...

Glutamine ratio is key ovarian cancer indicator

May 5, 2014
A Rice University-led analysis of the metabolic profiles of hundreds of ovarian tumors has revealed a new test to determine whether ovarian cancer cells have the potential to metastasize, or spread to other parts of the body. ...

Ovarian cancer cells hijack surrounding tissues to enhance tumor growth

September 4, 2012
Tumor growth is dependent on interactions between cancer cells and adjacent normal tissue, or stroma. Stromal cells can stimulate the growth of tumor cells; however it is unclear if tumor cells can influence the stroma.

How the breast cancer cells transform normal cells into tumoral ones?

November 13, 2014
Researchers at the Bellvitge Biomedical Research Institute of Bellvitge, the Catalan Institute of Oncology and the University Hospital of Bellvitge have participated in an international study published in the journal Cancer ...

Cancer-killing virus combined with a chemotherapy drug might effectively treat recurrent ovarian cancer

November 13, 2014
In six out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and five-year survival is only 27 percent. A new study suggests that a cancer-killing virus combined with a chemotherapy drug might safely and ...

Anti-leukemia drug may also work against ovarian cancer

November 17, 2014
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer - and likely other cancers as well, report researchers at the University of California, ...

Recommended for you

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.